Ichnos Glenmark Innovation unveils ISB 2301 tri-targeting solid tumors
NewsBytes | May 20, 2026 9:40 PM CST
IGI's BEAT platform powers ISB 2301
ISB 2301 uses IGI's BEAT platform to combine multiple ways of attacking tumors: think antibody action, blocking cancer defenses, and keeping the immune response going strong.
CEO Lida Pacaud calls this approach a big step forward for precision cancer treatment.
IGI aims to start clinical trials in 2027 after filing an IND application by the end of 2026, while Glenmark Pharmaceuticals Limited informed stock exchanges about the development through a regulatory filing.
READ NEXT
-
Capricorn Tarot Horoscope Today, May 22, 2026: Self-restraint will prevail, proceed with logic
-
Aquarius Tarot Horoscope Today, May 22, 2026: Stay Consistent and Show Your Creative Side
-
Horoscope Today: Astrological Forecast for May 22, 2026, for All Zodiac Signs
-
Libra Tarot Horoscope Today, May 22, 2026: Stay Proactive and Strengthen Your Management Skills
-
‘CID Tortured Me To Confess’: Man Alleges Wrongful Arrest In Suvendu Aide Murder Probe After Name Mix-Up
